Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes

Journal of the American Board of Family Medicine

Volumn 25, Issue 1, 2012, Pages 50-54

  Crouch, Michael A ^a   Mefford, Ivan N ^b   Wade, Ekpedeme U ^c  

^a Memorial Family Medicine Residency Program   (United States)

^b Fort Bend Premier Care   (United States)

^c NONE

Author keywords

Glycosylated hemoglobin A; Hb A1c; Proton pump inhibitors; Type 2 diabetes mellitus

Indexed keywords

GLITAZONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; NON PRESCRIPTION DRUG; PROTON PUMP INHIBITOR; SULFONYLUREA;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASIAN; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; ETHNICITY; FAMILY MEDICINE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RESIDENCY EDUCATION;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALS, COMMUNITY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAL AUDIT; METFORMIN; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84855656082     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2012.01.100161     Document Type: Article

References (26)

1. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-94.
2. Shaw J, Sicree R, Zimmet P. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2009;87:4-14.
3. Mahler RJ, Adler ML. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endo Metab 1999;84:1165-71. (Pubitemid 30644370)
4. Bell DSH. Current status of diabetes treatment. South Med J 2002;95:24-9. (Pubitemid 34131533)
5. Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes. Medl Hypotheses 2009;73:29-32.
6. Suarez-Pinzon WL, Yan Y, Rabinovitch A. Combination therapy with gastrin and glucagon-like peptide-1 (GLP-1) restores pancreatic insulin content and corrects hyperglycemia after diabetes onset in NOD mice. Can J Diabetes 2004;28:257.
7. Rooman I, Lardon J, Bouwens L. Gastrin stimulates B-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas. Diabetes 2002;51:686-90. (Pubitemid 34760176)
8. Cowey SL, Quast M, Belalcazar LM, et al. Abdominal obesity, insulin resistance and colon carcinogenesis are in creased in mutant mice lacking gastrin gene expression. Cancer 2005;103:2643-53. (Pubitemid 40800546)
9. Schubert ML, Makhlouf GM. Neural, hormonal and paracrine regulation of gastrin and acid secretion. Yale J Biol Med 1992;65:553- 60.
10. Parkinson J. A case of pernicious anaemia terminating in acute diabetes. Lancet 1910;II:416-8.
11. Rehfeld JF. Disturbed islet-cell function related to endogenous gastrin release. J Clin Invest 1976;58:41-9.
12. Rehfeld JF, Stadil F, Baden H, Fischermann K. The enteral insulin-stimulation after Whipple's operation. Diabetologia 1975;11:207-10.
13. Bryant JG, Smith JV. Zollinger-Ellison syndrome with pancreatic islet cell hyperplasia. Calif Med 1965;102:49-52.
14. Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC. Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 2006;49:2689-96. (Pubitemid 44510793)
15. Yoshihisa U., Susumu I, Yasuyuki M, et al. Effect of serum gastrin concentration on insulin resistance. Digestion Absorption 2006;28:42-5.
16. Creutzfeldt W. The consequences of hypergastrinemia. Yale J Biol Med 1994;67:709-23.
17. Gurden G, Boyacioglu S, Gul C, et al. Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients. Nephrol Dial Transplant 1999;14:2688-91. (Pubitemid 32208387)
18. Peach HG, Barnett NE. Helicobacter pylori infection and fasting plasma glucose concentration. J Clin Path 2001;54:466-9. (Pubitemid 32531097)
19. Hu Y-M, Mei Q, Xu X-H, Hu X-P, Hu N-Z, Xu J-M. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. World J Gastroenterol 2006;12:4750-3. (Pubitemid 44269739)
20. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001;33:32-5. (Pubitemid 32613575)
21. Cadiot G, Vissuzaine C, Pospai D, Ruszniewski P, Potet F, Mignon M. Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Gastroenterol Clin Biol 1995;19:811-7.
22. Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Therap 1990;4:131-8. (Pubitemid 20300401)
23. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician 2002;66:273-80. (Pubitemid 34810080)
24. Sanders SW, Tolman KG, Greski PA, Jennings DE, Hoyos PA, Page JG. The effects of lansoprazole, a new H+, K(+)-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992;6:359-72.
25. Banerjee S, Ardill JES, Beattie AD, McColl KEL. Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria. Aliment Pharmacol Ther 1995;9:507-12.
26. Suzaki F, Suzuki R, Sugiyama M. An increase of serum insulin by induced hypergastrinemia with proton pump inhibitor in type 2 diabetes. Prog Med 2004;24:661-4.